Table of Contents
- SemaGBA: How Semaglutide Regulates Appetite and Weight
- Abstract
- Study at a Glance
- Study Snapshot
- Study Facts Table
- What the Researchers Actually Did
- Key Findings: Primary Outcomes
- Key Findings: Secondary Outcomes and Subgroup Analyses
- Adverse Events and Safety Profile
- Statistical Approach and Rigor
- Clinical Takeaway
- Why This Matters Clinically
- CED Clinical Relevance
- Fits What We Already Know
- What This Study Teaches Us
- What It Does Not Show
- Fits the Broader Conversation
- Read This Paper Through Nine Different Lenses
- What is the SemaGBA model?
- How does the model predict semaglutide’s effects?
- What are the key findings of the SemaGBA study?
- How does the model simulate neural activity?
- What are the limitations of the SemaGBA model?
- Can the model be used to predict hypoglycemia risk?
- What does the model suggest about early intervention in prediabetes?
- How is the SemaGBA model validated?
- What are the implications of the model’s findings for future research?
- Is the SemaGBA model open access?
- Read next
SemaGBA: How Semaglutide Regulates Appetite and Weight
GLP-1 Receptor Agonist
Obesity & Type 2 Diabetes
Gut-Brain Axis
Computational Modeling
What You’ll Learn
- How the SemaGBA model integrates 14 metabolic and neural variables to simulate semaglutide’s mechanisms across type 2 diabetes, obesity, and prediabetes
- What the model predicts about AgRP, POMC, and dopamine neuron activity during semaglutide treatment — and why those predictions cannot yet be validated in humans
- Where computational modeling adds genuine explanatory value and where its assumptions require caution
- Why early intervention in prediabetes may preserve beta-cell function, and what this model’s limitations mean for clinical translation
Abstract
Aims: Semaglutide is a GLP-1 receptor agonist for the treatment of type 2 diabetes and obesity. Its clinical effects are well established, but the underlying mechanisms remain unclear. This study aimed to use computational modelling to generate hypotheses about semaglutide’s long-term metabolic (body weight, net energy intake, blood glucose, insulin, insulin sensitivity, glucotoxicity, leptin, leptin sensitivity, lipotoxicity, GLP-1, and beta-cell function) and neural (AgRP, POMC, and dopamine neural activity) effects.
Want to apply this research to your care?
CED Clinic translates emerging research into individualized clinical care. Dr. Caplan has treated 30,000+ patients.
Book a consultation →Materials and Methods: The SemaGBA computational model was developed in Julia using a system dynamics approach, integrating 14 metabolic and neural variables. A version without neural variables was first constructed and validated against clinical data for blood glucose and weight loss. The model was then extended with neural variables. Baseline variable profiles were defined for people with type 2 diabetes, obesity, and a healthy condition. Simulations were performed for semaglutide treatment over periods from 30 weeks to 5 years.
Results: The reduced model accurately reproduced clinical outcomes, predicting glucose reductions of 38.0 mg/dL (clinical data: 41.0 mg/dL) and weight loss of 3.2 kg (data: 3.8 kg) for type 2 diabetes (0.5 mg semaglutide), and 15.1% weight loss (data: 14.9%–17.1%) for obesity (2.4 mg semaglutide). Simulations demonstrated semaglutide’s interconnected mechanisms, including reduced lipotoxicity and glucotoxicity, enhanced beta-cell function, and glucose-dependent insulin secretion. Prediabetes intervention prevented progression to diabetes by preserving beta-cell function. Neural variables illustrated potential contributions of AgRP, POMC, and dopamine neuron activity to reduced net energy intake.
Conclusion: The SemaGBA model demonstrates how semaglutide achieves glucose control and weight loss through integrated metabolic and neural pathways. Validation is limited by data availability, but the framework provides hypotheses for future research into semaglutide’s neural effects.
DOI: https://doi.org/10.1111/dom.70722
Open Access: Yes (Creative Commons Attribution-NonCommercial-NoDerivs)
Study at a Glance
| Design | Computational system dynamics modeling study; no human participants enrolled |
| Population Simulated | Virtual population profiles representing type 2 diabetes, obesity, and healthy state; prediabetes via chronic overeating |
| Model Variables | 14 metabolic and neural variables (11 metabolic: body weight, blood glucose, insulin, GLP-1, leptin, net energy intake, insulin sensitivity, leptin sensitivity, beta-cell function, glucotoxicity, lipotoxicity; 3 neural: POMC, AgRP, dopamine neuron activity) |
| Validation Source | SUSTAIN 1 (T2D, 0.5 and 1.0 mg); STEP 1, 3, and 4 (obesity, 2.4 mg) phase 3 trial data |
| Simulation Duration | 30 weeks to 5 years depending on scenario |
| Key Finding | Model reproduced clinical weight loss and glucose outcomes within close range of observed values across all five validation datasets; neural variable outputs remain hypothesis-generating only |
Study Snapshot
| Study / Dose | Endpoint | Clinical Change | Model Prediction |
|---|---|---|---|
| SUSTAIN 1 / 0.5 mg (30 wk) | Fasting blood glucose | −41.0 mg/dL | −38.0 mg/dL |
| SUSTAIN 1 / 0.5 mg (30 wk) | Body weight | −3.8 kg | −3.2 kg |
| SUSTAIN 1 / 1.0 mg (30 wk) | Fasting blood glucose | −44.0 mg/dL | −45.4 mg/dL |
| SUSTAIN 1 / 1.0 mg (30 wk) | Body weight | −4.7 kg | −4.1 kg |
| STEP 1 / 2.4 mg (68 wk) | Body weight | −14.9% | −15.1% |
| STEP 3 / 2.4 mg (68 wk) | Body weight | −16.0% | −15.1% |
| STEP 4 / 2.4 mg (68 wk) | Body weight | −17.1% | −15.1% |
All baseline values and model predictions derived from Kennis & van Riel 2026, Table 1.
Study Facts Table
| Authors | Vivan C. W. Kennis, Natal A. W. van Riel |
| Journal / Year | Diabetes, Obesity and Metabolism, 2026 |
| Study Design | Computational system dynamics model; in silico simulation; no patient enrollment |
| N | No human participants; model calibrated and validated against phase 3 trial aggregate data |
| Intervention Modeled | Once-weekly subcutaneous semaglutide at 0.5 mg, 1.0 mg, or 2.4 mg with standard dose escalation |
| Comparator | Untreated (baseline) simulation trajectories; no placebo arm within model |
| Primary Endpoint | Reproduction of clinically observed changes in fasting blood glucose and body weight |
| Key Results | Model-predicted glucose and weight changes within 1–7% of observed clinical values across all five validation scenarios; neural variable outputs remain unvalidated |
| Adverse Events | Not applicable (computational model); paper notes the model could be used to investigate hypoglycemia risk |
| Funding | Dutch Research Council (NWO) |
| Conflicts of Interest | None declared |
What the Researchers Actually Did
Kennis and van Riel developed SemaGBA, a system dynamics model implemented in Julia, to simulate how semaglutide modulates a network of 14 interconnected metabolic and neural variables. The model uses differential equations to represent how each variable changes over time as a daily average. Dimensional variables — those with clinical units such as blood glucose (mg/dL) and body weight (kg) — are directly measurable. Dimensionless variables — insulin sensitivity, leptin sensitivity, beta-cell function, glucotoxicity, lipotoxicity, and the three neural activity variables — are normalized relative to a healthy baseline and represent processes not routinely captured in clinical settings.
Model construction followed a staged workflow. A reduced version omitting neural variables was calibrated iteratively against phase 3 trial data from SUSTAIN 1 (type 2 diabetes) and STEP 1, 3, and 4 (obesity). Once metabolic outputs were consistent with observed outcomes, the model was extended to include POMC, AgRP, and dopamine neuron activity, which were constrained to influence only net energy intake and each other, with a maximum deviation from the reduced model of 2.8% in the obesity simulation. Semaglutide’s pharmacokinetics were described using a first-order, single-compartment model with subcutaneous doses added every seven days beginning at day 7 of simulation, following the standard clinical escalation schedule (0.25, 0.5, 1.0, 1.7, and 2.4 mg). The drug was assumed to exert the same physiological effects as endogenous GLP-1.
Key Findings: Primary Outcomes
- At 0.5 mg semaglutide over 30 weeks in the type 2 diabetes simulation, fasting blood glucose decreased by 38.0 mg/dL (observed: 41.0 mg/dL) and body weight decreased by 3.2 kg (observed: 3.8 kg).
- At 1.0 mg semaglutide over 30 weeks, glucose decreased by 45.4 mg/dL (observed: 44.0 mg/dL) and body weight by 4.1 kg (observed: 4.7 kg).
- At 2.4 mg semaglutide over 68 weeks in the obesity simulation, body weight decreased by 15.1%, compared with observed values of 14.9% (STEP 1), 16.0% (STEP 3), and 17.1% (STEP 4).
- In the type 2 diabetes simulation, semaglutide reduced net energy intake by 5.5%, with beta-cell function rising from 0.50 to 0.89 and glucotoxicity falling from 0.50 to 0.37.
- In the obesity simulation, net energy intake fell by 26.0%, lipotoxicity decreased from 0.40 to 0.27, and beta-cell function improved from 0.80 to 1.4. Insulin secretion transiently rose to a maximum of 17.5 µU/mL before declining to 11.4 µU/mL as blood glucose normalized toward 90–95 mg/dL, consistent with the model’s representation of glucose-dependent insulin secretion.
Key Findings: Secondary Outcomes and Subgroup Analyses
- Prediabetes simulation: In a healthy individual modeled to chronically consume 2,700 kcal/day, untreated overeating produced obesity (BMI 30.4 kg/m²) within 27 months and type 2 diabetes (blood glucose ≥125 mg/dL) within 31 months. Initiating 1.0 mg semaglutide at day 245 (prediabetic phase) maintained blood glucose at approximately 101.0 mg/dL, keeping glucotoxicity at 0.006 versus 0.23 in the untreated trajectory and preserving beta-cell function at 1.57 versus 0.88 untreated. Because net energy intake was held constant in this simulation, weight-mediated variables (leptin, lipotoxicity) were unaffected.
- Neural variable simulation: POMC neuron activity increased in both diabetes and obesity simulations, driven primarily by semaglutide dosage escalation and rising insulin levels. AgRP activity declined initially due to insulin inhibition, then rose modestly as leptin levels fell. Dopamine neuron activity decreased in both simulations due to insulin and semaglutide inhibition, with a modest rebound late in each simulation as leptin declined. Maximum deviations in net energy intake between the reduced and extended models were 1.4% (diabetes) and 2.8% (obesity).
- The model predicted that declining leptin during treatment generates counter-regulatory appetite stimulation via AgRP, which the authors propose may attenuate semaglutide’s long-term effectiveness.
- The model also suggested that dopamine neuron activity responds earliest to semaglutide, implying that patients may experience reduced food reward before homeostatic satiety signals via POMC and AgRP pathways become dominant.
Adverse Events and Safety Profile
Statistical Approach and Rigor
SemaGBA is a deterministic system dynamics model; it produces single-trajectory outputs for defined initial conditions rather than probabilistic estimates with confidence intervals. Effect function parameters were calibrated iteratively by comparing model outputs to aggregate clinical trial means, not to individual patient data. No formal goodness-of-fit statistics, residual analyses, or sensitivity analyses are reported in the main text (supplementary materials contain additional detail). The model does not incorporate stochastic variability, so it cannot capture the distribution of individual responses seen in clinical practice. Validation was restricted to aggregate endpoints from five trials over a maximum of 68 weeks, leaving longer-term predictions unvalidated. The neural variable outputs are not calibrated to any human clinical data; their plausibility depends entirely on the physiological assumptions encoded in the effect functions.
Clinical Takeaway
SemaGBA provides a mechanistically grounded, computationally tractable framework for understanding why semaglutide produces the clinical outcomes observed in pivotal trials. The model’s close reproduction of blood glucose and weight loss endpoints across five phase 3 datasets is reassuring regarding its metabolic architecture. Clinicians should understand that the neural outputs — the AgRP, POMC, and dopamine trajectories — are hypothesis-generating constructs, not validated predictions. The prediabetes simulation is particularly speculative, as net energy intake was held constant (a condition that does not reflect clinical reality), producing pharmacologically unrealistic fasting insulin values above 90 µU/mL. The model’s greatest near-term utility is conceptual: it illustrates how semaglutide’s glucose-dependent insulin secretion, beta-cell preservation, and appetite suppression form an integrated, self-reinforcing system rather than isolated mechanisms.
Why This Matters Clinically
The mechanisms by which semaglutide produces sustained weight loss and glycemic improvement remain incompletely understood even after years of widespread clinical use. Most prior computational models of semaglutide described dose-response relationships for weight or glucose without integrating the feedback loops that produce those outcomes, and experimental neural data come from animal studies that have not been linked to metabolic endpoints or clinical measures. SemaGBA is the first published model to couple metabolic dynamics — beta-cell function, glucotoxicity, lipotoxicity, insulin and leptin sensitivity — with simulated neural activity in AgRP, POMC, and dopamine pathways, and to ground that coupled model in phase 3 human trial data. This matters because it provides a testable, mechanistically explicit framework that can guide the design of future human studies and, potentially, inform dose optimization or the identification of biomarkers that predict treatment response.
CED Clinical Relevance
At CED Clinic, patients receiving semaglutide often ask why the medication reduces their appetite, whether the effect is durable, and why some individuals plateau. SemaGBA offers a rigorous framework for answering those questions. The model’s depiction of declining leptin levels generating counter-regulatory appetite signals through AgRP neurons — partially offsetting semaglutide’s anorexigenic effect — aligns with what clinicians observe when appetite suppression attenuates over months of treatment. The prediabetes scenario reinforces the clinical case for early intervention before glucotoxic damage accumulates, a principle already central to CED’s approach. Importantly, the model’s limitations remind us that the neural architecture remains speculative: we should not overstate certainty about specific neural mechanisms to patients, even as the metabolic framework is well-grounded.
Fits What We Already Know
The SemaGBA model is grounded in well-established physiology. GLP-1’s stimulation of glucose-dependent insulin secretion, its enhancement of beta-cell mass through neogenesis and apoptosis inhibition, and its role in slowing gastric emptying are cited from prescribing information for Ozempic and Wegovy. The model’s depiction of lipotoxicity impairing beta-cell function and contributing to insulin resistance draws on the glucotoxicity-lipotoxicity convergence framework described by Poitout and Robertson (2002). The POMC and AgRP neuronal circuitry is consistent with Varela and Horvath (2012) and Wu and Zheng (2018). Experimental data confirming semaglutide’s effects on POMC, AgRP, and dopamine neurons in animal models come from multiple cited studies, including Kooij et al. (2024) and Zhu et al. (2025). The prediabetes intervention findings align directionally with the meta-analysis by Salamah et al. (2024) on GLP-1 receptor agonists in prediabetes, though semaglutide remains without FDA approval for this indication as of this publication.
What This Study Teaches Us
Semaglutide’s clinical effects arise from an interconnected system, not a single mechanism. Weight loss improves lipotoxicity, which in turn restores leptin and insulin sensitivity and protects beta-cell function. Semaglutide simultaneously reinforces this trajectory by directly enhancing beta-cell function and sustaining GLP-1 receptor activation at levels that prevent the compensatory appetite increases that would otherwise accompany caloric restriction and leptin decline. The neural layer adds a plausible explanation for early appetite suppression through dopamine pathways and sustained satiety through POMC activation, with AgRP activity tracking a counter-regulatory arc that may explain why some patients experience appetite attenuation over time. All of that neural narrative is hypothesis, not established fact — but it is a well-structured hypothesis built on a metabolic framework that does match clinical data.
What It Does Not Show
- The neural variable outputs (AgRP, POMC, dopamine) are not validated against any human clinical or imaging data. They represent one internally consistent solution, not the unique or correct mechanistic answer.
- The model does not capture individual patient variability; it produces single-trajectory outputs for population archetypes.
- The prediabetes simulation holds net energy intake constant, precluding weight loss and generating physiologically unrealistic fasting insulin levels (93.2 µU/mL), which limits its translational value.
- Glucagon dynamics — suppressed by semaglutide and clinically relevant to glucose regulation — are omitted.
- Fat depot location and distribution are not distinguished, despite their differential metabolic significance.
- Physiological adaptations to sustained weight loss (e.g., reduced resting metabolic rate) are not incorporated.
- Social, behavioral, and environmental drivers of food intake are excluded by design.
- Long-term predictions beyond 68 weeks (the maximum validation window) are extrapolations without clinical grounding.
- Treatment discontinuation, dose adjustment for tolerability, and non-responders are not modeled.
Fits the Broader Conversation
The field
Read This Paper Through Nine Different Lenses
The same evidence can produce very different conclusions depending on the question being asked. Explore this study through multiple physician-guided interpretive frameworks.
Overview
The SemaGBA model integrates metabolic and neural variables to simulate semaglutide’s effects on appetite, weight loss, and glucose control. It accurately reproduces clinical outcomes from phase 3 trials and generates hypotheses about the drug’s neural mechanisms.
Key findings include preserved beta-cell function with early intervention in prediabetes and potential counter-regulatory effects of declining leptin levels on long-term effectiveness.
- Model accurately predicts glucose reductions and weight loss.
- Neural variable outputs remain unvalidated hypotheses.
- Early semaglutide treatment preserves beta-cell function.
Patient Takeaway
For patients, the SemaGBA model suggests that early semaglutide treatment can help preserve beta-cell function and prevent diabetes progression. However, long-term effects like potential counter-regulatory appetite stimulation need further study.
The model’s neural hypotheses could inform personalized treatment strategies based on individual responses to semaglutide.
- Early intervention may prevent diabetes.
- Neural pathways influence appetite suppression.
- Long-term effectiveness requires ongoing research.
Clinician’s POV
Clinicians can use the SemaGBA model to understand semaglutide’s mechanisms, including its effects on metabolic and neural pathways. The model is validated against clinical data from phase 3 trials.
Insights into early intervention in prediabetes could inform treatment strategies for preventing diabetes progression.
- Model provides mechanistic insights.
- Validated by clinical trial data.
- Early intervention preserves beta-cell function.
A Skeptical Read
Skeptics should note that while the SemaGBA model accurately predicts clinical outcomes, its neural variable outputs remain unvalidated hypotheses. The model focuses on short-term effects and does not incorporate long-term variability.
Further research is needed to validate neural pathway predictions and explore long-term patient responses.
- Neural variables are unvalidated.
- Focuses on short-term outcomes.
- Long-term variability not considered.
Study Critic
Critics may point out that the SemaGBA model is deterministic and does not incorporate stochastic variability, limiting its ability to capture individual patient responses. The model’s focus on short-term data also restricts long-term predictions.
Further studies are needed to address these limitations and validate neural pathway hypotheses.
- Deterministic nature limits variability.
- No stochastic variability included.
- Short-term data focus.
Compared to Past Research
The SemaGBA model builds on the established clinical efficacy of semaglutide and other GLP-1 receptor agonists in treating type 2 diabetes and obesity. It provides a mechanistic framework to understand these drugs’ effects.
Historical data from phase 3 trials form the basis for validating the model’s predictions, ensuring its relevance to current clinical practices.
- Based on established clinical efficacy.
- Validated against historical trial data.
- Mechanistic understanding of GLP-1 agonists.
Practical Considerations
Practically, the SemaGBA model highlights the benefits of early semaglutide intervention in preserving beta-cell function and preventing diabetes progression. It also generates hypotheses about neural pathways that could inform future research.
Clinicians can use these insights to guide treatment decisions and explore potential new avenues for drug development.
- Early intervention preserves beta-cell function.
- Neural pathway hypotheses need validation.
- Guides clinical decision-making.
Future Directions
Future research should focus on validating the model’s neural variable outputs and exploring long-term patient responses to semaglutide. This could provide deeper insights into the drug’s mechanisms and improve treatment strategies.
Longitudinal studies are needed to address current limitations in understanding long-term effects and individual variability.
- Validate neural pathway hypotheses.
- Explore long-term patient responses.
- Address individual variability.
Misreadings & Bad-Faith Takes
Misreadings of the SemaGBA model could arise from interpreting neural variable outputs as validated conclusions rather than hypotheses. The model’s focus on short-term effects may also lead to misunderstandings about long-term patient outcomes.
It is crucial to recognize these limitations and avoid overinterpreting the model’s predictions without further validation.
- Neural variables are unvalidated.
- Short-term focus limits long-term predictions.
- Avoid misinterpretation of hypotheses.
Have thoughts on this? Share it:
What is the SemaGBA model?
The SemaGBA model is a computational system dynamics model that simulates how semaglutide affects metabolic and neural variables in type 2 diabetes, obesity, and prediabetes.
How does the model predict semaglutide’s effects?
The model integrates 14 variables to simulate changes in blood glucose, body weight, insulin sensitivity, and neural activity like AgRP, POMC, and dopamine.
What are the key findings of the SemaGBA study?
The model accurately predicts clinical outcomes for semaglutide in type 2 diabetes and obesity trials, showing reduced glucose levels and weight loss.
How does the model simulate neural activity?
The extended SemaGBA model includes neural variables to hypothesize about changes in AgRP, POMC, and dopamine neuron activity during semaglutide treatment.
What are the limitations of the SemaGBA model?
The neural variable outputs remain unvalidated and the model does not incorporate stochastic variability or long-term predictions beyond 5 years.
Can the model be used to predict hypoglycemia risk?
In principle, yes, as it simulates glucose and insulin dynamics, but this has not been specifically addressed in the study.
What does the model suggest about early intervention in prediabetes?
The model suggests that early semaglutide treatment can preserve beta-cell function and prevent progression to type 2 diabetes.
How is the SemaGBA model validated?
The model is validated against clinical data from five phase 3 trials, focusing on fasting blood glucose and body weight outcomes.
What are the implications of the model’s findings for future research?
The model provides hypotheses about semaglutide’s neural effects that can guide future clinical studies and drug development.
Is the SemaGBA model open access?
Yes, the study is published under a Creative Commons Attribution-NonCommercial-NoDerivs license.
